Overall survival results from the MONALESSA-3 phase III trial showed positive results for patients with advanced breast cancer, but toxicities related to the use of ribociclib still need to be addressed.
At the European Society of Medical Oncology (ESMO) 2019 Congress, overall survival results of the phase III MONALEESA-3 trial of postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with fulvestrant (faslodex) plus/minus ribociclib (kisqali) were discussed by leading experts across the globe.
At ESMO, OncLive®, a sister publication to Oncology Nursing News® had the chance to sit down with Patrick Neven, MD, PhD, GYN oncologist at University Hospital Leuven, Leuven, Belgium, and discuss the data from the MONALEESA-3 trial, focusing on the toxicities associated with patients who took ribociclib.
They are tolerated fairly well, but there are some hematologic toxicities. Some patients feel tired, they sometimes have anemia, they feel nauseous. There also might be a bit of hair loss, which can be disturbing. Grade 3 and 4 hematological toxicity was present in more than 10% of the patients, which is sometimes the reason to delay the dose or to reduce the dose.